atorvastatin has been researched along with Cognition Disorders in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Ge, X; Shi, M; Tai, Y; Tian, J; Xu, W; Zhao, C; Zhu, G | 1 |
| Choi, KC; Hong, DK; Kang, BS; Kho, AR; Park, KH; Park, WJ; Suh, SW | 1 |
| Canzian, JM; Duarte, MMMF; Duarte, T; Furian, AF; Grigoletto, J; Oliveira, CV; Oliveira, MS | 1 |
| Castro, AA; Lapa, FR; Matheus, FC; Prediger, RD; Santos, AR; Tasca, CI; Viola, GG; Wiemes, BP | 1 |
| Kalonia, H; Kumar, A; Mishra, J; Sharma, N | 1 |
| Lloyd, DG; Ma, D; O'Dea, KP; Pac-Soo, C; Penn, JW; Takata, M; Vizcaychipi, MP; Wan, Y; Watts, HR | 1 |
| Corrigan, B; Hooker, AC; Ito, K; Karlsson, MO; Plan, EL; Ueckert, S | 1 |
| Dal-Cim, TA; de Oliveira, KA; dos Santos, AA; dos Santos, VV; Farina, M; Martins, WC; Mendes-de-Aguiar, CB; Prediger, RD; Tasca, CI; Vandresen-Filho, S; Viola, GG | 1 |
| Li, X; Pan, Y; Wang, X; Yang, J | 1 |
| DU, H; Gu, P; Jiang, WM; Shao, JQ; Wang, J; Zhang, K | 1 |
| Abe, K; Ikeda, Y; Kozuki, M; Kurata, T; Matsuura, T; Miyazaki, K; Morimoto, N; Nagai, M; Ohta, Y; Panin, VL | 1 |
| Barone, E; Butterfield, DA; Cenini, G; Dowling, AL; Head, E; Mancuso, C; Martin, SB; Murphy, MP | 1 |
| Barone, E; Butterfield, DA; Cenini, G; Di Domenico, F; Head, E; Mancuso, C; Murphy, MP; Sultana, R | 1 |
| Adler, C; Browne, P; Connor, D; Lochhead, J; Lopez, J; Petanceska, S; Sabbagh, M; Soares, H; Sparks, DL; Ziolkowski, C | 1 |
| Browne, P; Connor, DJ; Lopez, J; Petersen, RB; Sabbagh, MN; Sparks, DL | 1 |
| Guyton, JR; Laskowitz, DT; Lynch, JR; Mace, B; Song, P; Wang, H; Warner, DS; Yang, HJ; Yates, RB | 1 |
3 trial(s) available for atorvastatin and Cognition Disorders
| Article | Year |
|---|---|
[Effects of atorfastatin on the cognitive function of patients with vascular cognitive impairment and different apolipoprotein E genotypes].
Topics: Aged; Apolipoproteins E; Atorvastatin; Cognition Disorders; Dementia, Vascular; Female; Genotype; Heptanoic Acids; Humans; Male; Middle Aged; Neuroprotective Agents; Pyrroles | 2010 |
Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT).
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Atorvastatin; Ceruloplasmin; Cholesterol; Cholinergic Antagonists; Cognition Disorders; Copper; Cross-Sectional Studies; Heptanoic Acids; Humans; Longitudinal Studies; Middle Aged; Peptide Fragments; Pyrroles; Verbal Learning | 2005 |
Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoproteins E; Atorvastatin; Cholesterol; Cognition Disorders; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neuropsychological Tests; Pyrroles; Severity of Illness Index; Treatment Outcome | 2006 |
13 other study(ies) available for atorvastatin and Cognition Disorders
| Article | Year |
|---|---|
Atorvastatin Relieves Cognitive Disorder After Sepsis Through Reverting Inflammatory Cytokines, Oxidative Stress, and Neuronal Apoptosis in Hippocampus.
Topics: Animals; Anxiety; Apoptosis; Astrocytes; Atorvastatin; Behavior, Animal; Cecum; Cognition Disorders; Cytokines; Glial Fibrillary Acidic Protein; Hippocampus; Inflammation Mediators; Learning; Ligation; Male; Memory Disorders; Mice, Inbred ICR; Morris Water Maze Test; Motor Activity; Neurons; Oxidative Stress; Punctures; Sepsis; Survival Analysis | 2020 |
The Effects of Atorvastatin on Global Cerebral Ischemia-Induced Neuronal Death.
Topics: Animals; Atorvastatin; Behavior, Animal; Brain Ischemia; Cognition Disorders; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Neurons; Neuroprotective Agents; Oxidative Stress; Rats; Rats, Sprague-Dawley | 2021 |
Effect of atorvastatin on behavioral alterations and neuroinflammation during epileptogenesis.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Cerebral Cortex; Cognition Disorders; Convulsants; Disease Models, Animal; Epilepsy; Female; Gene Expression Regulation; Hippocampus; Humans; Interleukin-1beta; Interleukin-6; Male; Mice; Mice, Inbred C57BL; Pilocarpine; Seizures; Status Epilepticus | 2018 |
Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Intranasal; Analysis of Variance; Animals; Antiparkinson Agents; Atorvastatin; Brain; Cognition Disorders; Cytokines; Disease Models, Animal; Food Preferences; Heptanoic Acids; Male; Maze Learning; Mood Disorders; Motor Activity; Parkinsonian Disorders; Pyrroles; Rats; Rats, Wistar; Social Behavior; Sucrose; Sweetening Agents; Swimming; Tyrosine 3-Monooxygenase | 2013 |
Synergistical neuroprotection of rofecoxib and statins against malonic acid induced Huntington's disease like symptoms and related cognitive dysfunction in rats.
Topics: Animals; Atorvastatin; Behavior, Animal; Brain; Cognition Disorders; Cyclooxygenase 2 Inhibitors; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Heptanoic Acids; Huntington Disease; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Malonates; Neurons; Neuroprotective Agents; Nootropic Agents; Oxidative Stress; Pyrroles; Rats; Rats, Wistar; Simvastatin; Sulfones | 2013 |
The therapeutic potential of atorvastatin in a mouse model of postoperative cognitive decline.
Topics: Administration, Oral; Animals; Atorvastatin; Cognition; Cognition Disorders; Disease Models, Animal; Dose-Response Relationship, Drug; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Memory; Mice; Mice, Inbred C57BL; Nephrectomy; Postoperative Complications; Pyrroles; Recovery of Function; Treatment Outcome | 2014 |
Improved utilization of ADAS-cog assessment data through item response theory based pharmacometric modeling.
Topics: Alzheimer Disease; Atorvastatin; Clinical Trials, Phase III as Topic; Cognition Disorders; Databases, Factual; Heptanoic Acids; Humans; Longitudinal Studies; Models, Biological; Pyrroles; Statistics as Topic | 2014 |
Atorvastatin Prevents Cognitive Deficits Induced by Intracerebroventricular Amyloid-β1-40 Administration in Mice: Involvement of Glutamatergic and Antioxidant Systems.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Animals; Atorvastatin; Cognition Disorders; Glutamic Acid; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infusions, Intraventricular; Male; Mice; Oxidative Stress; Peptide Fragments; Prefrontal Cortex; Recognition, Psychology; Spatial Learning; Spatial Memory | 2015 |
Atorvastatin attenuates cognitive deficits through Akt1/caspase-3 signaling pathway in ischemic stroke.
Topics: Animals; Atorvastatin; Brain Ischemia; Caspase 3; Cognition Disorders; Male; Maze Learning; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Signal Transduction; Stroke | 2015 |
Atorvastatin and pitavastatin improve cognitive function and reduce senile plaque and phosphorylated tau in aged APP mice.
Topics: Aging; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Atorvastatin; Body Weight; Brain; Cognition Disorders; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Maze Learning; Mice; Mice, Transgenic; Neuroprotective Agents; Organ Size; Phosphorylation; Plaque, Amyloid; Protein Processing, Post-Translational; Pyrroles; Quinolines; tau Proteins | 2011 |
Coenzyme Q10 and cognition in atorvastatin treated dogs.
Topics: Aging; Animals; Atorvastatin; Cognition Disorders; Dogs; Female; Heptanoic Acids; Male; Mitochondria; Oxidative Phosphorylation; Oxidative Stress; Parietal Lobe; Pyrroles; Ubiquinone | 2011 |
Atorvastatin treatment in a dog preclinical model of Alzheimer's disease leads to up-regulation of haem oxygenase-1 and is associated with reduced oxidative stress in brain.
Topics: Aldehydes; Alzheimer Disease; Animals; Anticholesteremic Agents; Atorvastatin; Brain; Cognition Disorders; Disease Models, Animal; Dogs; Glutathione; Heme Oxygenase-1; Heptanoic Acids; Ketocholesterols; Linear Models; Liver; Oxidative Stress; Pyrroles; Up-Regulation | 2012 |
Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Brain Edema; Brain Injuries; Brain Ischemia; Cerebrovascular Circulation; Chemotaxis, Leukocyte; Cognition Disorders; Cytokines; Disease Models, Animal; Encephalitis; Endothelial Cells; Heptanoic Acids; Hippocampus; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Neurons; Pyrroles; Recovery of Function; RNA, Messenger; Simvastatin; Treatment Outcome | 2007 |